February 13, 2006
(Date of earliest event reported)
LABORATORY CORPORATION
OF
AMERICA HOLDINGS
DELAWARE | 1-11353 | 13-3757370 | ||
(State or other jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA |
27215 | 336-229-1127 | ||
(Address of principal executive offices) | (Zip Code) |
(Registrant's telephone number including area code) |
ITEM 7.01. Regulation FD Disclosure
On February 13, 2006 Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced the availability of a test for genetic variants in the UGT1A1 gene associated with excessive toxicity in individuals treated with the late-stage colorectal cancer drug irinotecan hydrochloride (Camptosar®). The rights to perform the test have been sublicensed to LabCorp by the Mayo Foundation for Medical Education and Research.
Exhibits
99.1 Press Release dated February 13, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Laboratory Corporation of America Holdings (Registrant) |
||||
Date: February 15, 2006 | By: | /s/Bradford T. Smith | ||
Bradford T. Smith, Executive Vice President and Secretary |
||||